Lipid emulsions have been used to treat cardiovascular collapse due to local anaesthetic toxicity. However, there are few data available on the comparative efficiency of the partitioning properties of available lipid emulsions in clinical use. This in vitro study compared the buffering properties of the lipid emulsions Clinoleic™ 20% (Baxter, Old Toongabbie, NSW) and Intralipid ® 20% (Fresenius Kabi, Pymble, NSW) using both bupivacaine (Marcain ® 0.5%, AstraZeneca, North Ryde, NSW) and ropivacaine (Naropin ® 1%, AstraZeneca, North Ryde, NSW). The concentration of anaesthetic in buffer before and after mixing with lipid was quantified using chromatographic analysis. Bupivacaine was more effectively bound by the lipid agents, with a 40% reduction in initial concentration. Ropivacaine demonstrated a 20% reduction in concentration with the addition of lipid agents. Importantly, there was no significant difference between Intralipid and Clinoleic in terms of their buffering behaviour, suggesting equivalent binding efficacy.
Local anaesthetic toxicity can result in minor central nervous system manifestations and, if severe, may progress to confusion, restlessness, incoherent speech, seizures, respiratory arrest and finally to hypotension, arrhythmias, cardiovascular collapse and arrest 1 .
Infusions of emulsions composed of long-and medium-chain triglycerides have their traditional use in parenteral nutrition. They have been used in treating cardiovascular collapse due to local anaesthetic toxicity 2 . Weinberg has promulgated the use of Intralipid ® (Fresenius Kabi, Pymble, NSW) as a therapy for local anaesthetic toxicity 3 , and animal models have demonstrated that lipid infusion reverses cardiovascular depression associated with bupivacaine toxicity 3, 4 .
Two main theories exist to explain the mechanism of reversal of cardiovascular collapse following local anaesthetic toxicity. First, the lipid infusion provides a 'lipid sink' into which the anaesthetic agent is absorbed. This is supported by experiments demonstrating an oil emulsion extracting bupivacaine from plasma. Studies on isolated rat hearts show an increased recovery from bupivacaineinduced asystole through a decrease in cardiac bupivacaine content and increased bupivacaine washout 5 .
The second theory involves optimisation of carnitine acylcarnitine translocase, a carrier protein in the heart 6 . This enzyme functions as an antiport for carnitine and acylcarnitine movement between the cytosol and the mitochondria. Carnitine acylcarnitine translocase facilitates the entry of fatty acids into the mitochondria, where they are oxidised to produce adenosine triphosphate. Inhibition of this enzyme will lead to a decrease in cardiac adenosine triphosphate. It is thought that lipid rescue may cease inhibition by mass action.
Case studies have subsequently emerged reporting the successful use of Intralipid following cardiac arrest secondary to bupivacaine and levobupivacaine toxicity 7, 8 . A recent study also found that efficiency of binding may also vary depending on the lipid used, with Intralipid found to be two and a half times more efficient at binding local anaesthetic than a Medialipide ® (Lipofundin ® MCT/LCT 20%, B. Braun, Bella Vista, NSW) emulsion 9 .
The objective of this study was to compare the partitioning characteristics of two available lipid emulsions in clinical use, Clinoleic™ 20% (Baxter, Old Toongabbie, NSW) and Intralipid 20%. Intra-lipid and Clinoleic have not been compared in this manner before. Work done by Litonius et al compared Intralipid and Clinoleic in a porcine toxicology model 10 . They found no difference in plasma bupivacaine levels, but the mean bupivacaine concentration was 1.8 µg/ml. Peak plasma concentrations during anaesthetic regional blocks can vary widely; average concentrations have been reported from 1.6 µg/ml 11 to 2.2 µg/ml 12 . The toxic bupivacaine plasma concentration is thought to be 2 to 4 µg/ml 13 . Plasma concentrations do not infrequently exceed this level during routine regional blocks, with what would be considered safe doses 11, 14 . In addition to plasma concentration, toxicity is dependent on many factors such as the rate of change of plasma concentration, direct vascular injection, alpha-1 acid glycoprotein concentration, pH and electrolyte disturbance.
MATERIALS AND METHODS

Study design and medications
This in vitro experimental study was conducted at the Royal Brisbane and Women's Hospital. The local anaesthetics used were bupivacaine (Marcain ® 0.5%; AstraZeneca, North Ryde, NSW) and ropivacaine (Naropin ® 1.0%; AstraZeneca, North Ryde, NSW). The lipid emulsions were Intralipid 20% and Clinoleic 20%. These parenteral lipid emulsions consist of droplets up to 500 nm in diameter with a monolayer of phospholipids enveloping a triglyceride core. Intralipid 20% contains 20% soybean oil, as well as other long chain fatty acids. Intralipid 20% also contains other elements including lipid soluble vitamins, peroxidation products and phytosterols 15 . Clinoleic is composed entirely of refined olive oil (80% volume) and refined soybean oil (20% volume) with 1.5 mmol of phosphorus per 100 ml. In contrast, Medialipide is a mixture of 50% by weight soybean oil and 50% coconut oil.
Experiments
The partitioning of bupivacaine and ropivacaine from phosphate buffered saline (PBS) into lipid (Intralipid and Clinoleic) were investigated by quantifying the concentration of anaesthetic in buffer before and after mixing with lipid. The samples were then centrifuged; the lipid aspirated to waste and 100 µl of buffer removed for chromatographic analysis of the concentration. All experiments were done in triplicate to minimise variability in the partitioning process at 25°C.
Each local anaesthetic agent was separately diluted in PBS at pH 7.4 to standard concentrations of 500, 250, 125, 62.5, 31.25, 15.625, 7.81, 3.9, 1.95, 0.97 and 0.48 µg/ml. The PBS solution contained NaCl (8 g/l), KCl (0.2 g/l), Na 2 HPO 4 (1.44 g/l), KH 2 PO 4 (0.24 g/l) and accounted for the presence of NaCl in bupivacaine.
Each of the two lipids were separately added to each of the two sets of buffered local anaesthetic (1.95 to 250 µg/ml, with an anaesthetic-free PBS control). The emulsion local anaesthetic buffer solution was prepared immediately before use to maintain stability. The lipid (50 µl) was added to the buffered anaesthetic standards (950 µl) in a 1.5 ml microfuge tube and immediately vortexmixed for three seconds. The samples were further mixed by rotation for ten minutes, then centrifuged at 18,000 relative centrifugal force for ten minutes to separate the upper lipid layer from the lower buffer layer. The lipid was aspirated to waste and an aliquot (100 µl) of buffer transferred to a high performance liquid chromatography vial for analysis. The high performance liquid chromatography system comprised of Waters modular equipment: 510 pump, 717+ autosampler and 486UV detector controlled via Empower2 software (Milford, MA, USA). The mobile phase was 35% methanol, 35% acetonitrile and 30% 30mM phosphate buffered to pH 5.6 pumped at 1.5 ml/ minute. The stationary phase was a Phenomenex Gemini C18 column (150 × 4.6 mm) with a matching guard cartridge (Phenomenex Inc, Lane Cove, NSW). Bupivacaine eluted at 3.7 minutes and ropivacaine at 3.1 minutes.
Samples and calibration standards were directly injected together in batches to generate a calibration line. Calibration standards (0.488 to 250.0 µg/ml) were used to validate the linearity, precision and accuracy of the quantification. Bupivacaine and ropivacaine peak areas were measured by ultraviolet spectrophotometry at 215 nm, and concentrations were back calculated from a calibration line.
Statistical analysis
Statistical analysis was conducted using PASW ® Statistics 18 (SPSS Inc, Chicago, IL, USA). The relationship between the initial 'free' anaesthetic concentration (in g/ml) and concentration postpartitioning in the lipid phase (in g/ml) were determined by a linear regression model. The linearity assumption was first confirmed by a scatterplot of post-partitioning concentration by initial anaesthetic concentration. Percent reduction in final concentration was calculated as:
(Initial concentration -final concentration / initial concentration)*100 The association of anaesthetic agent (two categories), lipid (two categories) and initial concen-Anaesthesia and Intensive Care, Vol. 41, No. 5, September 2013 tration (seven categories) with percent reduction in final concentration was evaluated using factorial analysis of variance. A P value <0.05 was considered statistically significant for independent variables or interactions between variables.
RESULTS
The performance of the assay was well within the acceptance criteria for calibrators and replicate analysis expected in bioanalysis. The lipid binding of each local anaesthetic was linear across the range of initial concentrations (Figure 1 ). Greater lipid binding was observed for bupivacaine than for ropivacaine ( Figure 2) .
Differences between the two lipids in terms of binding capacity appeared minimal (Figure 1 ), although some variation in percent binding was observed for Intralipid and Clinoleic over the range of initial concentrations for ropivacaine ( Figure  2) . The mean and standard deviation of the final buffered anaesthetic concentration and percent reduction from baseline are shown in Tables 1 and 2 for each level of initial anaesthetic concentration.
All three experiments were performed at each concentration level for each local anaesthetic and lipid combination. A 2 by 2 by 7 factorial analysis of variance tested the effects of anaesthetic agent, lipid and initial concentration on percent reduction in concen-tration. There was a significant main effect for anaesthetic agent (degrees of freedom [df]=1, F ratio [F]=761.8, P <0.001) and initial concentration (df=6, F=2.69, P=0.023), but not for lipid (df=1, F=3.46, P=0.068). The two main effects were qualified, however, by a significant interaction between anaesthetic agent and initial concentration (df=6, F=12.0, P <0.001) and lipid and initial concentration (df=6, F=5.99, P <0.001).
A 2 by 7 factorial analysis of variance was therefore performed separately for each anaesthetic to analyse the effect of lipid and initial concentration on percent reduction. For bupivacaine, the only main effect was the initial concentration (df=6, F=7.08, P <0.001) and there was no significant interaction between lipid (df=1, F=1.10, P=0.303), or the interaction of lipid with initial concentration (df=6, F=0.12, P=0.993). For ropivacaine, initial concentration (df=6, F=8.17, P <0.001), as well as the interaction with lipid and initial concentration (df=6, F=28.6, P <0.001), were significant factors; lipid was not significant as a main effect (df=1, F=3.55, P=0.070).
DISCUSSION
This study identified that both bupivacaine and ropivacaine are bound by the lipid agents, Intralipid and Clinoleic, with the potential to reduce the toxic effects of these local anaesthetics in a clinical setting. Bupivacaine was more effectively bound by the lipid agents with a 40% reduction in initial concentration, while ropivacaine demonstrated a 20% reduction in concentration with the addition of lipid agents. For bupivacaine, slightly higher degrees of binding were observed at higher concentrations of the anaesthetic, while ropivacaine uptake demonstrated a more complex association with initial concentration and the lipid agent used. The lipid agent used did not have a main effect on the percent reduction in anaesthetic concentration for either anaesthetic, suggesting that Clinoleic 20% and Intralipid 20% can be used interchangeably when a lipid formulation is needed in the treatment of cardiovascular collapse secondary to local anaesthetic toxicity.
Clinoleic and other lipid therapies were introduced because of concerns regarding the traditional use of soybean oil-based therapies. The omega-6 polyunsaturated fatty acid linoleic acid makes up 50% of soybean oil-based compounds. A number of in vitro studies have found that linoleic acid can exert immunosuppressive effects 16 , such as inhibition of T cell activation, T cell proliferation and interleukin-2 production. Furthermore, inhibition of neutrophil chemotaxis and migration, impairment of the reticuloendothelial system and reduction of bactericidal capacity have been found to occur with both in vitro and in vivo studies 17 . However, these results have not been consistent throughout the literature. The concern in the critical care setting is one of possible harm, with sepsis being a pro-inflammatory and then immunosuppressed state and the theory that n-6 polyunsaturated fatty acids are both pro-inflammatory and immunosuppressive.
It seems prudent, then, that a toxic and iatrogenically-induced state of local anaesthetic overdose should not have a treatment that is possibly proinflammatory and immunosuppressive if a better one is available. The argument could be made that the treatment is, in comparison, a short-term one compared to infusions in the intensive care setting. Although animal studies have shown changes in the expression of the interleukin-2 receptor after six hours in rats with linoleic acid-based treatment, Clinoleic had a positive effect on interleukin-2 receptor expression 18 . Mean and standard deviation (SD) are calculated from three experiments performed at each initial concentration level for each local anaesthetic and lipid combination. Mean and standard deviation (SD) are calculated from three experiments performed at each initial concentration level for each local anaesthetic and lipid combination.
A limitation of this study was that it was conducted at pH 7.4 and at room temperature (25°C), and there is further scope to explore lipid binding in acidotic states and variable temperature conditions, which have been associated with variations in lipid anaesthetic binding affinity 14 . Bupivacaine was cleared in a greater amount than ropivacaine and it is assumed that levobupivacaine would generate similar results to bupivacaine. However, further studies regarding the partitioning of other drugs that have been successfully treated by lipid therapy are warranted.
CONCLUSION
In conclusion, this study contributes weight to the lipid sink hypothesis and provides support that the partitioning of local anaesthetics in two parenteral lipid emulsions is similar. While Intralipid and Clinoleic may have equivalent binding efficacy, Clinoleic has the potential advantage of not contributing to immunosuppression in a critically ill, at risk population. The increasing clinical use of lipid emulsions will add greater knowledge to local anaesthetic systemic toxicity and its optimal treatment.
